Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression

Abstract

Supplemental Digital Content is available in the text

Interventions for management of post-stroke depression: A bayesian network meta-analysis of 23 randomized controlled trials

“…Our results are consistent with those of several reviews [12][13][14]17 in demonstrating that SSRIs and TCAs significantly reduce the HAMD score than the control treatment. Interestingly, we conclude that reboxetine can improve the mood status of patients with PSD.…”

“…The main goals of PSD treatments include reduction of depressive symptoms and complete remission (no longer meeting the baseline criteria for depression) 13 . Meta-analyses found antidepressants to be significantly effective in reducing depressive symptoms 13,14 . However, when assessed by Diagnostic and Statistical Manual of Mental Disorders (DSM) or Hamilton Depression Rating Scale (HAMD), no clear evidence was found on whether antidepressants are effective for complete remission of PSD 13,15 .…”

Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery Study

“…While safety concerns mainly relate to SAEs, less serious but unpleasant side effects are likely to affect quality of life and willingness to continue treatment, which may affect the patient's future [16]. Some prognostic factors may predict some of these complications as it was reported for various post-stroke conditions [17][18][19][20][21][22]. In our study, more severe stroke, advanced age and the presence of some vascular risk factors increase the risk of SAEs.…”

Anxiety-Depressive Disorders in Patients After Stroke: Prevalence, Approaches to Diagnosis and Therapy

“…Неселективные препараты имеют преимущество при сочетании депрессивной симптоматики с другими расстройствами, а также сопутствующей центральной боли. Американские и европейские руководства рекомендуют использовать антидепрессанты в терапии постинсультных тревожно-депрессивных расстройств на протяжении не менее шести месяцев [64,66,67]. Принимая во внимание большое количество побочных эффектов у антидепрессантов, следует подбирать наиболее безопасные комбинации и дозы, учитывать тяжесть неврологических проявлений инсульта и имеющихся соматических заболеваний, а также избегать полипрагмазии.…”